Next Article in Journal
Dual-Agent Photodynamic Therapy with Optical Clearing Eradicates Pigmented Melanoma in Preclinical Tumor Models
Next Article in Special Issue
Actively Targeted Nanodelivery of Echinomycin Induces Autophagy-Mediated Death in Chemoresistant Pancreatic Cancer In Vivo
Previous Article in Journal
Use of Interferon Alfa in the Treatment of Myeloproliferative Neoplasms: Perspectives and Review of the Literature
Previous Article in Special Issue
Induction of Lysosome Membrane Permeabilization as a Therapeutic Strategy to Target Pancreatic Cancer Stem Cells
Open AccessReview

Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward

1
Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke University Hospital, 39120 Magdeburg, Germany
2
Department of General-, Visceral-, Vascular- and Transplant Surgery, Otto-von-Guericke University Hospital Magdeburg, 39120 Magdeburg, Germany
3
Department of Radiology and Nuclear Medicine, Otto-von-Guericke University Hospital, 39120 Magdeburg, Germany
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1955; https://doi.org/10.3390/cancers12071955
Received: 1 July 2020 / Revised: 13 July 2020 / Accepted: 15 July 2020 / Published: 18 July 2020
(This article belongs to the Special Issue Recent Advances in Pancreatic Ductal Adenocarcinoma)
Globally, the death rate of pancreatic ductal adenocarcinoma (PDAC) has doubled over 30 years and is likely to further increase, making PDAC a leading cause of cancer-related death in the coming years. PDAC is typically diagnosed at an advanced stage, and modified FOLFIRINOX or nab-paclitaxel and gemcitabine are the mainstay of systemic therapy. For elderly patients with good performance status, low-dose treatment can preserve quality of life without compromising cancer control or survival. Maintenance therapy should be considered in PDAC patients achieving disease control with systemic therapy. In particular, olaparib has demonstrated a progression-free survival benefit of 3.6 months in a subgroup of PDAC patients with germline BRCA1/2 mutations (ca. 10% of all PDAC). Pancreatic enzyme replacement therapy is often omitted in the treatment of patients with PDAC, with possibly deleterious consequences. Small intestinal bacterial overgrowth is highly prevalent in patients with PDAC and should be considered in the diagnostic algorithm of PDAC patients with bloating and diarrhea. Rivaroxaban has been associated with a reduced risk of thrombosis without an increase in major bleeding events, and its use should be considered in every patient with advanced PDAC undergoing systemic therapy. View Full-Text
Keywords: pancreatic ductal adenocarcinoma; palliative therapy; maintenance therapy; supportive therapy; biomarker; molecular subtypes; pancreatic enzyme replacement; prophylaxis of thromboembolisms; small intestinal bowel obstruction; staging pancreatic ductal adenocarcinoma; palliative therapy; maintenance therapy; supportive therapy; biomarker; molecular subtypes; pancreatic enzyme replacement; prophylaxis of thromboembolisms; small intestinal bowel obstruction; staging
MDPI and ACS Style

Franck, C.; Müller, C.; Rosania, R.; Croner, R.S.; Pech, M.; Venerito, M. Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward. Cancers 2020, 12, 1955. https://doi.org/10.3390/cancers12071955

AMA Style

Franck C, Müller C, Rosania R, Croner RS, Pech M, Venerito M. Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward. Cancers. 2020; 12(7):1955. https://doi.org/10.3390/cancers12071955

Chicago/Turabian Style

Franck, Caspar; Müller, Christian; Rosania, Rosa; Croner, Roland S.; Pech, Maciej; Venerito, Marino. 2020. "Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward" Cancers 12, no. 7: 1955. https://doi.org/10.3390/cancers12071955

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop